All In Biotech

Drug Trial Radar · NCT04303507

Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting

Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)

Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 4,652 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,652

Actual

Start

Apr 29, 2020

Primary completion

Mar 22, 2022

Study completion Mar 22, 2022

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is a double-blind, randomised, placebo-controlled trial that will be conducted primarily in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other persons at risk of contracting COVID-19, who can be followed reliably for 5 months. The initial aim was to recruit 40,000 participants and we predict an average of 400-800 participants per site in 50-100 sites. The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation), or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10mg base/kg (four 155mg tablets for a 60kg subject), followed by 155 mg daily (250mg chloroquine phosphate salt/ 200mg hydroxychloroquine sulphate) will be taken for 3 months. If the participant is diagnosed with COVID-19, they will take continue to take the study medication until: * 90 days after enrolment (i.e., completion of kit) * hospitalised due to COVID-19 disease (i.e., not for quarantine purposes) in which case they will stop, or * advised to stop by their healthcare professional for other reasons Episodes of symptomatic respiratory illness, including symptomatic COVID-19, and clinical outcomes will be recorded in the Case Record Form during the follow-up period. This study is funded by Wellcome Trust Grant reference 221307/Z/20/Z.

Conditions

  • COVID19
  • Coronavirus
  • Acute Respiratory Illnesses

Interventions

  • Chloroquine or HydroxychloroquineDrug

    A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of symptomatic COVID-19 infectionsTime frame: Approximately 90 days

Locations

25 sites in 10 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier et Universitaire de Zone Abomey-Calavi

    Abomey-Calavi, Benin

  • Hospital De Zone Allada

    Allada, Benin

  • University Hospital Center of Angre

    Abidjan, Côte d’Ivoire

  • University Hospital Center of Bouake

    Bouaké, Côte d’Ivoire

  • Sardjito Hospital

    Yogyakarta, Indonesia

  • Airlangga University Hospital (UNAIR)

    Surabaya, East Java, Indonesia

  • Husada Utama Hospital

    Surabaya, East Java, Indonesia

  • Bunda Thamrin Hospital

    Medan, North Sumatra, Indonesia

  • Murni Teguh Memorial Hospital

    Medan, North Sumatra, Indonesia

  • Fountain Healthcare Hospital

    Eldoret, Kenya

  • Mbagathi County Hospital

    Nairobi, Kenya

  • The Bamako Hospital of Dermatology

    Bamako, Mali

  • Hospital Of Mali

    Bamako, Mali

  • B.P. Koirala Institute of Health Sciences

    Dharān, Nepal

  • The Aga Khan University Hospital

    Karachi, Pakistan

  • Faculty of Tropical Medicine, Mahidol University

    Bangkok, Thailand

  • Birmingham & Solihull Mental Health NHS Trust

    Birmingham, United Kingdom

  • Brighton and Sussex University Hospitals NHS Trust

    Brighton, United Kingdom

  • University Hospitals Coventry and Warwickshire NHS Trust

    Coventry, United Kingdom

  • Rotherham, Doncaster And South Humber NHS Foundation Trust

    Doncaster, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Oxford University Hospital NHS Foundation Trust

    Oxford, United Kingdom

  • University Hospitals Of Morecambe Bay NHS Foundation Trust

    Kendal, Cumbria, United Kingdom

  • The Dudley Group NHS Foundation Trust

    Dudley, West Midlands, United Kingdom

  • Zambart

    Lusaka, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.